Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Exscientia AI Limited
With
AGO Research GmbH
Age
18–125
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Minimum age 18 years
Signed informed consent form
Confirmed diagnosis of ovarian cancer except low grade serous, clear cell and mucinous histology
Where patients are treatment naïve, patients need to have disease stage FIGO (International Federation of Gynecology and Obstetrics) III or FIGO IV.
Patient is expected to receive primary chemotherapy/maintenance after initial surgical debulking or a further line of systemic therapy in the relapsed setting according to treatment guidelines
Feasibility of collecting malignant ascites and/or pleural effusion during either primary debulking surgery or a routine drainage procedure prior to initiation of the first or next line of systemic therapy
Known or suspected HIV or active Hepatitis B and/or C infection or active COVID-19 infection
Anticancer treatment or radiation therapy of the region which is to be drained or biopsied within the last 4 weeks
Patient unfit or not willing to receive any further systemic treatment
Patient is treated with therapeutics not tested in the assay - with the exception of anti-VEGF (Vascular endothelial growth factor) therapy
Known pregnancy
Sample quality criteria are not met (at least 250ml of ascites available, no signes of bacterial superinfection, no additives, at least 1% EpCAM (Epithelial Cell Adhesion Molecule) positive cells, viability at least 60%)
Clareo Health | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
